Message #19 From:
Stock News Bot Date: June 28, 2006 11:06:00 AM
MCDG News CytoCore to present at JP Turner Broker Conference
CHICAGO--(BUSINESS WIRE)--June 28, 2006--CytoCore, Inc. (OTCBB:MCDG) announced that its CEO, David Weissberg, and CFO, Robert McCullough Jr., will represent the Company at JP Turners annual in-house conference for new company investment ideas on July 7th and 8th at the Turner headquarters in Atlanta, Ga.
JP Turner invites 12 companies annually to present themselves as investment opportunities to JP Turner's broker base of 700 retail brokers.
About JP Turner
J.P. Turner & Company, L.L.C. is one of the Nation's fastest growing retail brokerage firms, providing services on behalf of securities professionals and their client investors. The firm was born with a desire to meet a standard of excellence that is characteristic of only the finest brokerages in the United States. http://www.jpturner.com/.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
